GlaxoSmithKline Says European Commission Approves Stem-Cell Therapy
May 27 2016 - 11:59AM
Dow Jones News
LONDON--GlaxoSmithKline PLC (GSK.LN) said Friday that the
European Commission has approved Strimvelis, the stem-cell gene
therapy aimed at treating patients with a rare immunodeficiency
disease called ADA-SCID.
The healthcare company said Strimvelis is indicated for the
treatment of patients with ADA-SCID for whom no suitable human
donor is available.
The marketing-authorization decision was based on data collected
from 18 children treated with Strimvelis, the company said.
Shares at 1500 GMT were down 4 pence, or 0.3%, at 1453 pence,
valuing the company at 70.78 billion pounds ($104 billion).
Write to Olga Cotaga at olga.cotaga@wsj.com, Twitter
@OlgaCotaga
(END) Dow Jones Newswires
May 27, 2016 11:44 ET (15:44 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
Gsk (LSE:GSK)
Historical Stock Chart
From May 2023 to May 2024